Relmada Therapeutics, Inc. RLMD
3.11 USD +0.25 (+8.93%)
Regular-session close
3.11 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
2.84 Day range 3.16
2.84 52-week range 8.00
- YTD
- -35.61%
- 1 year
- -25.60%
No chart data for this range yet.
- Market cap
- 331.82M
- EPS (ttm)
- -0.73
- Shares out
- 30.17M
- Forward P/E
- -0.19
- YTD return
- -35.61%
- 1-year return
- -25.60%
- 50-day average
- 2.53
- 200-day average
- 3.33
- Volume
- 1.71M
- Avg volume
- 1.42M
- Open
- 2.88
- Previous close
- 2.86
- Day's range
- 2.84 – 3.16
- 52-week range
- 2.84 – 8.00
- Beta
- 0.41
- Price target
- 0.86667 (-72.1%)
Key statistics
- Enterprise value
- 27.93M
- Price / book
- 0.13
- Free cash flow
- -18.51M
- Total cash
- 70.44M
- Return on equity
- -100.41%
- Short % of float
- 4.23%
Fundamental scorecard
6 of 25 checks passed on RLMD’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
RLMD Revenue — quarterly 0
RLMD Net income — quarterly -13.86M
RLMD EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.65 | -0.72 | -0.07 | -10.77% |
| Aug 7, 2024 | Jun 1, 2024 | -0.83 | -0.59 | +0.24 | +28.92% |
| May 8, 2024 | Mar 1, 2024 | -0.90 | -0.72 | +0.18 | +20.00% |
| Mar 19, 2024 | Dec 1, 2023 | -0.88 | -0.84 | +0.04 | +4.55% |
| Nov 8, 2023 | Sep 1, 2023 | -0.95 | -0.73 | +0.22 | +23.16% |
| Aug 8, 2023 | Jun 1, 2023 | -0.92 | -0.84 | +0.08 | +8.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Mizuho | down | Outperform | Neutral |
| Dec 4, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Jun 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 15, 2023 | Mizuho | reit | Buy | Buy |
| Jan 23, 2023 | SVB Leerink | main | — | Outperform |
| Oct 14, 2022 | Goldman Sachs | down | Buy | Neutral |
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relmada.com
News
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript Relmada Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate. Cash and Equivalents $202.1M.
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Your note
Sign in to keep a note on RLMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASAMENTO CHARLES J | Director | Stock Gift | Oct 21, 2024 | 0 |
| ENCE CHARLES | Officer | Purchase | Jan 30, 2024 | 38,970 |
| KELLY PAUL EDWARD | Director | Purchase | Sep 8, 2024 | 212,295 |
| O'GORMAN CEDRIC | Officer | Purchase | May 22, 2023 | 10,121 |
| SHENOUDA MAGED R | Chief Financial Officer | Purchase | Sep 10, 2024 | 88,335 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | Sep 10, 2024 | 384,024 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 13.16% | 1,302,151 | 494.30K | Sep 29, 2024 |
| Vanguard Group Inc | 12.70% | 1,256,705 | 477.05K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 11.99% | 1,186,452 | 450.38K | Sep 29, 2024 |
| Parsons Capital Management, Inc. | 10.13% | 1,002,695 | 380.62K | Sep 29, 2024 |
| Palo Alto Investors Lp | 7.40% | 732,400 | 278.02K | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.82% | 674,833 | 256.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8.61% | 851,916 | 323.39K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.78% | 374,029 | 141.98K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 3.57% | 353,625 | 134.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.59% | 157,021 | 59.60K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.01% | 100,177 | 38.03K | Sep 29, 2024 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.94% | 93,077 | 35.33K | Oct 30, 2024 |
